Ernexa Therapeutics Inc. Warrants (ERNAW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Ernexa Therapeutics Inc. Warrants Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 160,000 | $4,480 | $8,032 | $3,552 | 79.29% |
| BO Brian Oliveira Clear Street Group Inc. | 149,499 | $4,193.11 | $7,474.95 | $3,281.84 | 78.27% |
Ernexa Therapeutics Inc. Warrants (ERNAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ernexa Therapeutics Inc. Warrants ever had a stock split?
Ernexa Therapeutics Inc. Warrants Profile
| Biotechnology Industry | Healthcare Sector | Sanjeev Luther CEO | NASDAQ (NMS) Exchange | 114082118 CUSIP |
| US Country | 5 Employees | - Last Dividend | - Last Split | 19 Oct 1992 IPO Date |
Overview
Eterna Therapeutics Inc. is an innovative life science company, established in 2018 and headquartered in Cambridge, Massachusetts. Specializing in mRNA cell engineering technologies, Eterna is at the forefront of developing solutions for cell reprogramming and gene editing. Through a strategic license agreement with Factor Bioscience Limited, Eterna Therapeutics leverages cutting-edge research to pave the way for advancements in genetic therapies and biotechnology.
Products and Services
- mRNA Cell Reprogramming and Gene Editing
- NoveSlice and UltraSlice Gene-Editing Proteins
- ToRNAdo mRNA Delivery System
This core technology offered by Eterna Therapeutics revolutionizes how scientists approach genetic manipulation, enabling precise alterations in the genetic makeup of cells. It is foundational for developing treatments for genetic disorders and advancing regenerative medicine.
Eterna's proprietary gene-editing proteins, NoveSlice and UltraSlice, represent groundbreaking tools in the field of genome editing. These proteins allow for highly efficient and targeted modifications of DNA, providing a robust platform for therapeutic development and biomedical research.
The ToRNAdo mRNA Delivery System is a state-of-the-art technology developed by Eterna for the efficient delivery of mRNA therapeutics. This system ensures that mRNA can be delivered to target cells with high efficacy, a crucial aspect for the success of mRNA-based therapies.
